These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 14639675)

  • 21. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
    Pogarell O; Gasser T; van Hilten JJ; Spieker S; Pollentier S; Meier D; Oertel WH
    J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):713-20. PubMed ID: 12023411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease.
    Sung YH; Chung SJ; Kim SR; Lee MC
    Mov Disord; 2008 Jan; 23(1):137-40. PubMed ID: 17987649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
    Rektorová I; Rektor I; Bares M; Dostál V; Ehler E; Fanfrdlová Z; Fiedler J; Klajblová H; Kulist'ák P; Ressner P; Svátová J; Urbánek K; Velísková J
    Eur J Neurol; 2003 Jul; 10(4):399-406. PubMed ID: 12823492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.
    Rabey JM; Prokhorov T; Miniovitz A; Dobronevsky E; Klein C
    Mov Disord; 2007 Feb; 22(3):313-8. PubMed ID: 17034006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
    Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
    Mizuno Y; Yanagisawa N; Kuno S; Yamamoto M; Hasegawa K; Origasa H; Kowa H;
    Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
    Lemke MR; Brecht HM; Koester J; Reichmann H
    J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.
    Zarate CA; Payne JL; Singh J; Quiroz JA; Luckenbaugh DA; Denicoff KD; Charney DS; Manji HK
    Biol Psychiatry; 2004 Jul; 56(1):54-60. PubMed ID: 15219473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease.
    Barone P; Lamb J; Ellis A; Clarke Z
    Mov Disord; 2007 Mar; 22(4):483-9. PubMed ID: 17115380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.
    Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2006 Aug; 7(5):407-17. PubMed ID: 16815748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
    Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
    J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.